Exchange: NASDAQ·Updated 04:10 PM EDT
News
all
press releases
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Theravance Biopharma, Inc. (NASDAQ: TBPH) to Zymeworks Inc. for $17.00 per share. Halper Sadeh encourages Theravance shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary...
Business Wire
More News
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance's Q2 earnings match estimates. Cost cuts and a $929 million Zymeworks deal follow ampreloxetine's discontinuation.
Zacks
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update PR Newswire DUBLIN, Aug. 10, 2026 Previously announced acquisition by Zymeworks expected to...
PR Newswire
electroCore, Inc. (ECOR) Reports Q2 Loss, Tops Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +19.51% and +0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Stevanato Group (STVN) Q2 Earnings Top Estimates
Stevanato (STVN) delivered earnings and revenue surprises of +6.67% and -0.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of +12.50% and +6.27%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +26.11% and +6.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders?
Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, July 9, 2026 Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed...
PR Newswire
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--TBPH, IRDM, LCII, and PATK PR Newswire NEW YORK, July 9, 2026 NEW YORK, July 9, 2026 /PRNewswire/ -- Class...
PR Newswire
Theravance Stock Down 3% After Zymeworks Announces Buyout
TBPH falls after agreeing to a $929 million all-cash acquisition by Zymeworks, following a strategic review triggered by its failed ampreloxetine program.
Zacks

Advertisement|Remove ads.